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This is a simple but effective modification of a disposable
item in the hand set. It avoids the need for expensive pro-
tective goggles and face masks, and allows for safe pressure
irrigation of small contaminated wounds on the hand.
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BOTULINUM TOXIN: 28 PATIENTS AFFECTED
BY FREY’S SYNDROME TREATED WITH
INTRADERMAL INJECTIONS
Sir:
Frey’s syndrome, or gustatory sweating, is a phenomenon
frequently seen after total parotidectomy and surgery on the
temporal-mandible articulation. It is characterized by hyper-
hidrosis and facial flushing, especially in the parotid regions,
during eating.1 Although this syndrome takes its name from
Lucie Frey,2 it was first reported by Baillarger in 18533 and not
by Duphenix, as is commonly cited.4
The mechanism by which this disorder manifests itself
arises from damage to postganglionic parasympathetic fibers
of the auriculotemporal nerve that terminate in the parotid.
After removal of the parotid, these regenerated fibers go on
to innervate the vessels and sweat glands of the face. This
alteration of anatomy produces the local flushing and
hyperhidrosis.5–8
Although Frey’s syndrome is almost inevitable after pa-
rotidectomy, only about 50 percent of patients are symptom-
atic, and of these, only half judge their symptoms to be “im-
portant or embarrassing.”9 For this latter group, numerous
medical and surgical treatments have been proposed to pre-
vent or treat this condition, with limited success in some
cases.10–13
The aim of our study was to verify the effectiveness of a
newmethod, the intradermal injection of botulinum toxin.
Botulinum toxin inhibits the presynaptic release of acetyl-
choline. It blocks the interference between the auriculo-
temporal nerve fibers of the parotid and the sweat glands
of the skin.
Twenty-eight patients affected by Frey’s syndrome were
included in the study. All had complaints essentially of gus-
tatory hyperhidrosis, with 10 reporting, in addition, a visible
facial erythema in the parotid region that was particularly
evident in the presence of gustatory stimulation. The gusta-
tory stimulation was evoked in the clinic by making the pa-
tients eat sour-tasting foods (e.g., lemon juice). Four param-
eters were considered in each hemifacial zone: temperature
and color of the skin, quantity of sweat, and surface area
involved. The contralateral side of the face was used as a
control. The temperature of the skin was measured using a
digital contact thermometer; the local erythema was evalu-
ated using a digital chromometer; and the quantity and sur-
face area of sweating weremeasured using laboratory blotting
paper and an iodine-sublimated paper histogram (a modern
variant of the more traditional “test of minor”14). After de-
marcating the superficial skin and looking at clinical symp-
toms, using a demographic pencil, the botulinum toxin was
introduced intradermally using a 30-caliber needle. Multiple
doses of 0.1 ml (5 U) were injected, with a distance of 1 cm
between injection sites. Patients were subdivided into two
groups based on the administered dose and the size of the
zone treated. Group 1 received a dose of 20 U (0.4ml); group
2 received a dose of 75 U (1.5 ml). A lower dose was given to
the group 1, whose patients had slight symptoms; the dose was
limited to a 5-cm2 area of superficial skin. Group 2 received
a higher dose, as it included those patients affected by more
marked symptoms.
In all the treated patients, the injection of botulinum toxin
resulted in either the complete disappearance or an obvious
improvement in symptoms attributable to Frey’s syndrome
between the fourth and sixth days of treatment. No secondary
side effects were reported by the patients or noted by the
examiners, apart from a slight discomfort during intradermal
injection of the toxin. Follow-up examinations were per-
formed on days 4 and 6 and at 1 month, 3 months, and every
3 months thereafter for 2 consecutive years.
The duration of symptomatic remission appeared to be
more directly dependent on the administered dose rather
than the intensity of the symptoms before treatment. For
group 1 (low concentration, 20 U), remission lasted 9 6 2
months, whereas for the patients who received the toxin at a
higher concentration the duration of effect was 16 6 4
months. After 9 months, about 85 percent of the group 1
patients were already positive for screening, whereas in the
group 2 the positivity was less than 3 percent after the same
period.
When the effect wears off, the botulinum toxin can be
administered again, with a longer-lasting effect achieved with
the same initial dose.
These cases appear to confirm the clear advantages that
intradermal administration of botulinum toxin is able to
bring to patients with gustatory sweating (Frey’s syn-
drome). Since there is no evidence of side effects, it makes
this method of treatment the first choice. This method is,
however, only a temporary treatment for symptomatic re-
lief and not a definitive resolution, although the toxin is
easy to administer, economic in terms of cost, effective, and
always well tolerated.
The dosages used are those in the therapeutically effective
range, according to the literature examined.15 In every case,
we feel certain that symptomatic remission in terms of in-
tensity and duration depends essentially on the dose of bot-
ulinum toxin used.
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BILATERAL STAHL’S EAR:
A RARELY SEEN ANOMALY
Sir:
Stahl’s ear is a rare congenital ear anomaly that is char-
acterized by the presence of a third antihelical crus that
flattens and steers the helical rim posteriorly and superiorly.
Although it has been described as a rarely seen congenital ear
anomaly, it is relatively more common in Asia, especially in
Japan. It is seen bilaterally in 20 percent of cases.1–3 The
literature includes studies by Binder,4 Marx,5 Yamada and
Fukuda,6 Skoog,7 Fischl,8 and others9,10 about how Stahl’s ear
anomaly forms, but lately it is believed that this deformity is
caused by an error in the development of the helix and
scapha, approximately in the third embryologic month.1,9 In
this ear deformity, the main feature is that the free margin of
the helix is longer than the outer margin of the auricula, and
the helix does not fold in. This situation is just the opposite
of the normal ear shape. For reconstruction, a full-thickness,
wedge-shaped, third crus excision is needed.11
A 9-year-old girl presented to our clinic because of her ear
deformity. We diagnosed her as having bilateral Stahl’s ear
deformity with an indistinct third antihelical crus and a flat-
tened helical rim (Fig. 1, left). In this case, for an adequate
aesthetic result, classic wedge excision of the third crus would
not be enough and total wedge excision of the third crus
would make the ear smaller. We therefore modified the clas-
sic triangular wedge excision, as we did not finish the whole
triangular shape. The excision became trapezoidal in shape.
We added two more triangular excisions at the lateral sides
and a smaller triangular excision at the top of the trapezoid
to narrow the scapha, to prevent a dog-ear deformity and to
get an adequate rotation of the helical rim. Another reason
for such modification is to excise more abnormal third crus
formation closer to the helix and scaphoid region and to
prevent disturbing the regular antihelix and triangular fossa
formation (Fig. 1, left). Full-thickness excisions were made
according to the planned drawings. Auricular cartilage was
sutured with 5-0 monofilament polydioxanone, and skin was
closed with 6-0 monofilament polyvinyl difluoride sutures.
Gentle pressure dressings were applied to the ears after the
operation. There were no problems during the postoperative
follow-up period. At postoperative month 3, the patient and
her parents were fully satisfied with her new ears (Fig. 1, right).
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